Your browser doesn't support javascript.
loading
HOGVAX: Exploiting epitope overlaps to maximize population coverage in vaccine design with application to SARS-CoV-2.
Schulte, Sara C; Dilthey, Alexander T; Klau, Gunnar W.
Afiliación
  • Schulte SC; Algorithmic Bioinformatics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Electronic address: sara.schulte@hhu.de.
  • Dilthey AT; Institute of Medical Microbiology and Hospital Hygiene, University Clinic Düsseldorf, Düsseldorf, Germany. Electronic address: alexander.dilthey@med.uni-duesseldorf.de.
  • Klau GW; Algorithmic Bioinformatics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Electronic address: gunnar.klau@hhu.de.
Cell Syst ; 14(12): 1122-1130.e3, 2023 12 20.
Article en En | MEDLINE | ID: mdl-38128484
ABSTRACT
The efficacy of epitope vaccines depends on the included epitopes as well as the probability that the selected epitopes are presented by the major histocompatibility complex (MHC) proteins of a vaccinated individual. Designing vaccines that effectively immunize a high proportion of the population is challenging because of high MHC polymorphism, diverging MHC-peptide binding affinities, and physical constraints on epitope vaccine constructs. Here, we present HOGVAX, a combinatorial optimization approach for epitope vaccine design. To optimize population coverage within the constraint of limited vaccine construct space, HOGVAX employs a hierarchical overlap graph (HOG) to identify and exploit overlaps between selected peptides and explicitly models the structure of linkage disequilibrium in the MHC. In a SARS-CoV-2 case study, we demonstrate that HOGVAX-designed vaccines contain substantially more epitopes than vaccines built from concatenated peptides and predict vaccine efficacy in over 98% of the population with high numbers of presented peptides in vaccinated individuals.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Límite: Humans Idioma: En Revista: Cell Syst Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Límite: Humans Idioma: En Revista: Cell Syst Año: 2023 Tipo del documento: Article